Welcome To The Resverlogix HUB On AGORACOM

**Apabetalone (RVX-208) Currently Being Tested in a Phase 3 BETonMACE Cardiovascular Outcomes Trial and Will Soon Begin Phase 2a Kidney Dialysis and Phase 1 Fabry Disease Trials**

Free
Message: Another application/indicati... for the compound libraries

Selective BET bromodomain inhibition as an antifungal therapeutic strategy

https://www.ncbi.nlm.nih.gov/pubmed/28516956

Candida albicans is a major human fungal pathogen. Resverlogix and Zenith have thousands of compounds in their small molecule libraries. Several of these may be able to discriminate CaBdf1 from human BET bromodomain proteins.

"These findings establish BET inhibition as a promising antifungal therapeutic strategy and identify Bdf1 as an antifungal drug target that can be selectively inhibited without antagonizing human BET function."

"In summary, CaBdf1 and human BET BDs have distinct BETi-binding activity, supporting the feasibility of targeting CaBdf1 BDs with highly selective small-molecule inhibitors."

BDAZ

Share
New Message
Please login to post a reply